News

Aventa Genomics Celebrates Milestone with New CMS Determination

Aventa Genomics Celebrates Milestone with New CMS Determination

Aventa Genomics Marks a Key Milestone in Cancer Diagnostics

Aventa™ Genomics, LLC has achieved a significant milestone by receiving a favorable pricing determination from the Centers for Medicare and Medicaid Services (CMS) for its innovative Aventa FusionPlus test. This next-generation sequencing test aims to enhance cancer diagnostics by detecting critical gene fusions, translocations, and rearrangements in solid tumors using patient samples.

What is the Aventa FusionPlus Test?

The Aventa FusionPlus test is designed to analyze genetic material obtained from formalin-fixed, paraffin-embedded (FFPE) tumor tissue. By leveraging advanced 3D genomics technology, the test enhances the detection of novel breakpoints and fusion partners, boasting a signal amplification of 100 to 1000 times compared to conventional methods. This groundbreaking approach not only reveals actionable biomarkers but also identifies those that traditional methodologies often overlook.

The Importance of Favorable Pricing

Chris Roberts, Executive Director for Aventa Genomics, expressed the significance of obtaining favorable pricing from CMS, stating, "This determination highlights the importance of innovation in cancer diagnostics and enables us to continue to expand clinician access to our novel 3D genomics-based test." By integrating the Aventa FusionPlus into cancer diagnosis and management, the company aims to improve outcomes for patients with solid tumors.

Decision Impacts on Healthcare Providers

This pricing determination reflects the growing recognition of the need for advanced diagnostic tools in oncology. In addition, the Aventa FusionPlus test was granted a Proprietary Laboratory Analysis (PLA) code, which streamlines the process for healthcare providers to incorporate this test into patient care. Starting January 1, 2025, the pricing for the Aventa FusionPlus test will be effective, facilitating its broader implementation in clinical settings.

Accessing the Aventa FusionPlus Test

Aventa Genomics ensures that healthcare professionals can easily access and order the Aventa FusionPlus test through their laboratory services. Detailed information for providers, including requisition forms, is readily available on the company's official website.

About Aventa Genomics

Aventa Genomics, LLC specializes in the application of 3D genomics to improve patient outcomes. As a subsidiary of Arima Genomics, Inc., Aventa is dedicated to utilizing innovative tools for the identification of druggable targets in cancer treatment. Their flagship Aventa FusionPlus test stands as a testament to their commitment to advancing cancer diagnostics.

About Arima Genomics Inc.

Arima Genomics is on a mission to enhance human health by unlocking comprehensive insights into genomic structures. Their advanced technologies provide researchers and clinicians with a deep understanding of the three-dimensional organization of the genome, facilitating progress in identifying biomarkers and developing new therapeutic solutions for better patient management.

Frequently Asked Questions

1. What is the significance of the CMS pricing determination?

The CMS pricing determination is a critical milestone that facilitates access to the Aventa FusionPlus test, allowing more clinicians to incorporate advanced diagnostics into their practices.

2. How does the Aventa FusionPlus test differ from traditional methods?

The Aventa FusionPlus test utilizes 3D genomics technology, which significantly enhances the detection capabilities and reveals biomarkers often missed by conventional tests.

3. When will the pricing for the Aventa FusionPlus test take effect?

The CLFS pricing for the Aventa FusionPlus test will become effective on January 1, 2025.

4. How can healthcare providers order the Aventa FusionPlus test?

Healthcare providers can order the Aventa FusionPlus test by accessing detailed requisition forms available on the Aventa Genomics website.

5. What role does Arima Genomics play in Aventa Genomics?

Arima Genomics, as the parent company of Aventa Genomics, supports the development and implementation of advanced genomic technologies aimed at improving cancer diagnosis and treatment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 85

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 56

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 136

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 171

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 96

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 203

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 139

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading

Top 5 Most Recently Viewed Articles

SpinLaunch's Innovative Technology Set to Transform Satellite Deployment

Updated Category News Views 545

Revolutionizing Satellite Launches with Kinetic Energy SpinLaunch has achieved a remarkable milestone by securing $30 million in a Series C funding round, propelled by the support of ATW Partners and Kongsberg Defence and Aerospace. This brings the total amount raised by the company to an impressive $203 million, demonstrating robust confidence in its innovative approach...

Continue Reading
Micron Technology’s Remarkable Q4 Performance Driven by AI Boom

Updated Category News Views 91

Micron Technology Proves Analysts Wrong with Impressive Earnings Micron Technology, Inc. delivered a phenomenal earnings report that surprised many doubters and analysts, reporting a nearly 100% increase in revenues year-over-year. This significant growth was largely attributed to the booming demand for artificial intelligence (AI) solutions. It’s noteworthy that prior...

Continue Reading
M&T Bank Corporation Declares Quarterly Dividends for Preferred Stock

Updated Category News Views 107

Quarterly Cash Dividends Announced by M&T Bank Corporation M&T Bank Corporation (NYSE: MTB) has declared its quarterly cash dividends for its series of perpetual preferred stock. This announcement comes as part of M&T's commitment to provide consistent returns to its shareholders. Details of the Dividends The company specified two significant dividend payouts. The first...

Continue Reading
Market Trends: Powell's Impact and Tech Earnings in Focus

Updated Category News Views 171

Market Overview: A Day of Mixed Signals In a climate filled with uncertainty, U.S. equities showed a mixed performance, reflecting investors' cautious approach ahead of a crucial Federal Reserve policy decision. The Dow Jones Industrial Average (DJIA) edged up by 0.2%, reaching 47,681.66, driven by gains in industrials and energy sectors. Meanwhile, the S&P 500 (SPX)...

Continue Reading
Revolutionizing Urinary Incontinence Treatment with Altaviva™

Updated Category News Views 296

Introducing the Altaviva™ Device by Medtronic The Altaviva™ device is set to change the landscape of treating urge urinary incontinence. Medtronic plc (NYSE: MDT), a leader in healthcare innovation, has received FDA approval for this remarkable implantable tibial neuromodulation device. This device targets a significant health issue affecting millions, making...

Continue Reading